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ABSTRACT 
Background: Plasma lipid abnormalities commonly persist in patients with 
diabetic dyslipidemia in spite of statin monotherapy. 
Objective: The aim of this study was to determine whether fenofibrate plus 
low-close nicotinic acid adequately improves the lipoprotein profile in patients 
with diabetic dyslipidemia who are being treated with a statin. 
Methods: In this open-label, crossover study, patients with type 2 diabetes mel- 
litus who were receiving statin treatment were enrolled at the Lipid Clinic of 
the Veterans Affairs Medical Center, Dallas, Texas, and administered simvastatin 
20 mg/d for 8 weeks. At the end of the 8-week period, fenofibrate 160 mg/d was 
added for 8 weeks, followed by the addition of extended-release nicotinic acid 
1 g/d for an additional 8 weeks. The first subject was recruited on September 
25, 2003, and the last subject was recruited on September 28, 2004. Liver 
function tests, creatine phosphokinase activity, and blood glucose levels were 
assessed every 4 weeks to assess tolerability. Levels of fasting plasma lipids 
and lipoprotein cholesterol were measured every 8 weeks on 3 consecutive 
clays in each patient; C-reactive protein, lipoprotein pattern, and glycosylated 
hemoglobin levels were assessed once every 8 weeks. Plasma levels of total 
cholesterol, triglycerides, very-low-density lipoprotein plus intermediate- 
density lipoprotein cholesterol (VLDL+IDL-C), low-density lipoprotein cho- 
lesterol, high-density lipoprotein cholesterol (HDL-C), and apolipoprotein B 
were also measured. 
Results: Twenty-six patients were enrolled in the study and 20 patients 
(18 men, 2 women; mean [SD] age, 58.8 [6.5] years) completed it. The mean 
plasma triglyceride level was significantly decreased (-29.2%; P = 0.004) and the 
mean HDL-C level was significantly increased (+13.5%; P < 0.001) with 3-drug 
treatment (simvastatin + fenofibrate + extended-release nicotinic acid) com- 
pared with simvastatin monotherapy. Significant reductions in plasma levels of 
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VLDL+IDL-C (-35.7%; P = 0.001), VLDL+IDL-apolipoprotein B (-30%; P = 0.005), 
non-HDL-C (-12.9%; P = 0.001), and total-apolipoprotein B (-17.9%; P < 0.001) 
were seen with the 3-drug treatment compared with simvastatin alone. 
Compared with simvastatin monotherapy, simvastatin + fenofibrate-treated 
(2-drug treatment) patients had significantly lower plasma levels of triglyc- 
erides (-24.9%; P = 0.014) and significantly higher levels of HDL-C (45.4%; P = 
0.008). Significant reductions were also seen in levels of VLDL+IDL-C (-28.6%; 
P = 0.004), VLDL+IDL-apolipoprotein B (-26.7%; P < 0.001), non-HDL-C (-9.1%; 
P = 0.004), and total-apolipoprotein B (-12.3%; P< 0.001) in the 2-drug treatment 
group compared with the simvastatin monotherapy group. The administration 
of 3-drug treatment was associated with improved responses in all lipoprotein 
fractions, although only the increase in HDL-C level was statistically significant 
(47.7%; P = 0.008) compared with 2-drug treatment. 
Conclusions: Treatment with the 3-drug regimen was associated with a sig- 
nificant reduction in triglyceride levels compared with simvastatin monother- 
apy. However, there was not a significant incremental reduction in triglyceride 
levels when nicotinic acid was added to the 2-drug treatment, suggesting that 
the triglyceride-lowering effect of fenofibrate +nicotinic acid is not cumulative. 
To obtain clinically meaningful responses, particularly for the treatment of ele- 
vated HDL-C, higher doses of nicotinic acid might be required. (Curr Ther Res 
Clin Exp. 2006;67:321-333) Copyright © 2006 Excerpta Medica, Inc. 
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INTRODUCTION 
Type 2 diabetes mellitus is associated with a high risk for atherosclerotic cardio- 
vascular disease (ASCVD). 1 Several studies have demonstrated that cholesterol- 
lowering treatment, notably with 3-hydroxy-3-methylglutaryl coenzyme A reduc- 
tase inhibitors (statins), reduces the risk for ASCVD events in patients with 
diabetes. 2-5 Even so, atherogenic (diabetic) dyslipidemia (high serum triglyceride 
levels, low levels of high-density lipoprotein cholesterol [HDL-C], and small parti- 
cles of low-density lipoprotein cholesterol [LDL-C]) persists in many diabetic 
patients despite statin treatment. 6,7 The presence of this residual ipid abnor- 
mality raises the question of whether adding other lipid-lowering drugs that 
specifically target diabetic dyslipidemia will produce an improvement in the 
lipoprotein profile beyond that seen with statin monotherapy. Two lipid-lowering 
drugs of this type are fibrates and nicotinic acid. Representative studies found 
through a MEDLINE search (key terms: fenofibrate, nicotinic acid, statin, and 
metabolic syndrome) observed that both fibrates 8,9 and nicotinic acid 1°-12 have 
favorable ffects on dyslipidemia in patients with type 2 diabetes. 
Several clinical trials that included patients with diabetes have been carried 
out with fibrate treatment. 13-17 These trials have found either a significant 
reduction in ASCVD events with fibrate treatment or a strong but nonsignificant 
improvement. Although there has been a concern about using fibrates in com- 
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bination with statins because of an increased risk for severe myopathy, 18 this 
concern has been alleviated by the finding that 1 fibrate, fenofibrate, can be 
used with statins with little increase in the risk for myopathy. 17,19 However, in a 
clinical trial involving 9795 patients with type 2 diabetes, fenofibrate was asso- 
ciated with a nonsignificant reduction in ASCVD risk. 17 In fact, fenofibrate treat- 
ment did not significantly reduce major coronary events, the pr imary end point, 
although the total number of ASCVD events was significantly lower. Fenofibrate 
treatment was particularly ineffective in raising HDL-C levels. 
Nicotinic acid administered at relatively high doses has been found to have 
greater efficacy in patients with atherogenic dyslipidemia than fibrates because of 
its greater ability to raise HDL-C levels. 2°,21 Limited clinical trial data suggest hat 
nicotinic acid is associated with a reduction of the risk for cardiovascular disease 
in patients with diabetes. 22,23 Unfortunately, higher doses of nicotinic acid have 
been associated with significant adverse effects. In patients with diabetes, nico- 
tinic acid might worsen glycemic control. 1°,12 In recent studies, however, lower 
dosages of nicotinic acid (1-1.5 g/d) have been associated with moderate fficacy 
in lipid lowering without significantly worsening hyperglycemia in patients with 
diabetes. 12 The 1-g/d dosage has been found to be particularly well tolerated. 
In 1 open-label clinical trial, the combination of a fibrate (clofibrate) and 
nicotinic acid was found to significantly reduce (-60%; P < 0.01) the risk for 
coronary  heart disease mortal ity in 216 myocardial infarction survival patients 
with elevated levels of triglycerides. 24That study raised the possibil ity that the 
combination of a fibrate and nicotinic acid might have enhanced efficacy over 
either drug alone in the treatment of diabetic dyslipidemia. If so, it might be 
possible to formulate a fibrate + nicotinic acid combination. 
The present study was carried out to determine whether fenofibrate com- 
bined with low-dose nicotinic acid is more effective than fenofibrate alone when 
used in combination with a statin. If so, the combination of fenofibrate and low- 
dose nicotinic acid might be more desirable for the treatment of diabetic dys- 
lipidemia than higher doses of nicotinic acid alone. 
PATIENTS AND METHODS 
Patients aged _>18 years with type 2 diabetes mellitus were recruited into the 
study. Diabetes was defined according to the criteria of the American Diabetes 
Association and Report of the Expert Committee on the Diagnosis and Classifi- 
cation of Diabetes Mellitus guidelines. 25 All patients had metabolic syndrome, 
as defined by the updated National Cholesterol Education Program Adult 
Treatment Panel III criteria. 26 Patients had levels of plasma triglycerides ranging 
from 150 to 800 mg/dL, LDL-C level >100 mg/dL while receiving statin treatment, 
and HDL-C level <40 mg/dL. Fasting blood glucose was <200 mg/dL and glyco- 
sylated hemoglobin (HbAlc) was <9%. Patients had either been given dietary 
restrictions to follow to treat diabetes mellitus or they were receiving hypo- 
glycemic agents other than thiazolidinediones. 
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Patients were excluded if they had any endocrine disorder other than dia- 
betes mellitus, renal or hepatic impairment, infectious diseases, congestive 
heart failure, unstable angina or inadequately controlled hypertension, chemi- 
cal dependency, or cognitive impairment. Patients receiving drugs with known 
effects on plasma lipids (eg, steroids, postmenopausal hormone replacement 
treatment, and thiazolidinediones) were also excluded. Patients were excluded 
if they were receiving insulin. Women who were pregnant or breastfeeding were 
also excluded. 
The study was conducted at the Lipid Clinic of the Veterans Affairs Medical 
Center at Dallas, Dallas, Texas. The institutional review board at the Veterans 
Affairs Medical Center at Dallas reviewed and approved the study. All patients 
gave written informed consent o participate in the study. The study was con- 
ducted in accordance with the principles of the Declaration of Helsinki 27 and 
the Good Clinical Practice guideline. 28 
The study had a sequential design and consisted of 3 treatment phases. Each 
phase lasted 8 weeks during which patients were seen every 4 weeks. In the first 
phase, patients were either started on simvastatin 20 mg/d or had their statin 
dosage adjusted to this regimen; in phase 2, fenofibrate 160 mg/d was added to 
the statin treatment. This phase of the study was designated as 2-drug treat- 
ment. In phase 3, extended-release nicotinic acid* 1 g/d was added to the com- 
bination of fenofibrate + simvastatin (3-drug treatment). Adherence to treat- 
ment was monitored by pill count. 
Liver function tests, creatine phosphokinase activity, and blood glucose lev- 
els were determined every 4 weeks to assess tolerability. Levels of fasting plas- 
ma lipids and lipoprotein cholesterol were measured every 8 weeks on 3 con- 
secutive days in each patient; C-reactive protein, lipoprotein pattern, and HbAlc 
levels were assessed once every 8 weeks. 
Plasma levels of total cholesterol, triglycerides, very-low-density lipoprotein 
plus intermediate-density lipoprotein cholesterol (VLDL+IDL-C), LDL-C, HDL-C, 
and apolipoprotein B were measured as detailed previously. 29LDL sizes were 
measured using the Lipoprint system (Quantimetrix Inc., Redondo Beach, Cali- 
fornia). C-reactive protein was measured using a BN-100 immunonephelometer 
(Dade Behring, Inc., Deerfield, Illinois). 3° 
Statistical Analysis 
The primary end point of the study was the reduction in levels of plasma 
triglycerides when the combination of fenofibrate + low-close nicotinic acid 
was added to simvastatin treatment. On the basis of previous studies, 7,]° it was 
expected that the drug combination would produce a 30% reduction in plasma 
triglycerides. Because it was expected that some patients would drop out 
because of the length and complexity of the trial, the decision was made before 
study initiation to continue the study until a total of 20 patients had completed 
*Trademark: Niaspan TM (Kos Pharmaceuticals Inc., Miami, Florida). 
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all 3 phases. The secondary end point was an increase in plasma HDL-C level by 
adding the combination of fenofibrate +low-dose nicotinic acid to simvastatin 
treatment; he expected increase was 30%. It was estimated that 20 patients 
would be required to achieve a statistical significance of P < 0.05 with an SD of 
15% of the mean change for both end points. Other measures were considered 
tertiary end points and were not included in the sample-size calculation. 
Standard tolerability parameters were assessed by evaluating the preva- 
lences of the new-onset of poor glycemic ontrol or worsening lycemic ontrol 
during treatment and of muscle-related symptoms and/or serum aminotrans- 
ferase activities outside the normal range. Descriptive data are expressed as 
mean (SD). Comparisons of means were carried out among study phases using 
repeated-measures analysis of variance without Bonferroni corrections for mul- 
tiplicity of testing. Percentage changes for measures were expressed as the dif- 
ference between the means of the baseline and treatment phases divided by the 
mean of the baseline phase multiplied by 100. 
RESULTS 
Twenty-six patients entered the study and 20 patients (18 men, 2 women; mean 
[SD] age, 58.8 [6.5] years) completed it (Table I). Six patients failed to complete 
Table I. Baseline demographic and clinical characteristics of study patients with type 2 
diabetes (N = 20).* 
Characteristic Value 
Age, mean (SD), y 58.8 (6.5) 
Sex, no. (%) 
Male 18 (90) 
Female 2 (10) 
Body mass index, mean (SD), kg/m 2 33.9 (5.4) 
Body fat, mean (SD), %t 32.7 (2.8) 
Waist circumference, mean (SD), cm 109.9 (12.2) 
Glycosylated hemoglobin, % 6.5 (0.7) 
Glucose, mean (SD), mg/dL 131 (33) 
Duration of diabetes, mean (SD), y 6.7 (5.3) 
Hypertension, no. (%) 19 (95) 
Dietary treatment alone for diabetes, no. (%) 4 (20) 
Smoker, no. (%) 4 (20) 
13-Blocker treatment, no. (%) 3 (15) 
Coronary heart disease, no. (%) 2 (10) 
* Data were obtained at the time of recruitment when the patients were receiving various doses f 
statins. 
t Measured by bioelectrical impedance. 
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all 3 phases. One patient requested withdrawal due to fatigue during phase 2; 
1 patient developed excessive hyperglycemia prior to treatment with nicotinic 
acid; 2 patients experienced intolerable flushing episodes associated with nico- 
tinic acid; and 2 patients withdrew for no specified reason. 
For the 20 patients who completed the study, the addition of fenofibrate + 
nicotinic acid to simvastatin (3-drug treatment) was associated with a signifi- 
cantly reduced mean level of plasma triglycerides (-29.2%; P = 0.004) versus 
simvastatin monotherapy  (Tables II and III). The same treatment was associ- 
ated with a significantly raised mean HDL-C level (+13.5%; P < 0.001). It also was 
associated with significantly lowered mean levels of VLDL+IDL-C (-35.7%; 
P = 0.001), VLDL+IDL-apolipoprotein B (-30.0%; P = 0.005), non-HDL-C (-12.9%; 
P = 0.001), and total-apolipoprotein B (-17.9%; P < 0.001). 
Compared with simvastatin monotherapy, simvastatin + fenofibrate (2-drug 
treatment) was associated with a significantly lowered mean level of plasma 
triglycerides (-24.9%; P = 0.014) and a raised mean HDL-C level (+5.4%; P = 0.008) 
(Tables II and III). It was also associated with a significantly reduced mean 
level of VLDL+IDL-C (-28.6%; P = 0.004), VLDL+IDL-apolipoprotein B (-26.7%; 
P < 0.001), non-HDL-C (-9.1%; P = 0.004), and total-apol ipoprotein B (-12.3%; 
P < 0.001). Two-drug treatment also was associated with a significantly reduced 
mean total cholesterol evel (-5.9%; P = 0.018) compared with simvastatin 
monotherapy. 
None of the lipid levels were reduced significantly with 3-drug treatment 
compared with 2-drug treatment. However, the mean HDL-C level was signifi- 
cantly increased, by an additional 7.7% (P = 0.008), with 3-drug treatment, which 
brought he increase in HDL-C to +13.1% with the addition of 2 drugs to the sim- 
vastatin treatment regimen. 
Both the 2-drug and 3-drug regimens were associated with significant increases 
in the mean size of LDL particles (both, P< 0.001) and the percentage of large LDL 
(both, P < 0.001) compared with simvastatin monotherapy, but the increase was 
numerically but statistically nonsignificantly larger with 3-drug treatment than 
with 2-drug treatment (Tables II and III). The opposite was observed for the per- 
centage of small LDL, which was reduced more with 3-drug treatment than with 
2-drug treatment (both, P < 0.001). Thus with both 2-drug and 3-drug regimens, 
the ratio of large LDL to intermediate + small LDL was significantly increased (P = 
0.024 and P = 0.008, respectively), but the increase was significantly greater with 
the 3-drug treatment compared with 2-drug treatment (P = 0.045). 
With 3-drug treatment, fasting plasma glucose was significantly higher com- 
pared with 2-drug treatment (+16.7%; P = 0.035) and with simvastatin monother-  
apy (Tables II and III). In contrast, compared with simvastatin alone, the per- 
centage increase in HbAlc was significantly higher with both 2-drug (+6.2%; P < 
0.001) and 3-drug (+6.2%; P = 0.009) treatments, but there was no significant differ- 
ence between the latter 2 regimens. No significant between-regimen differences 
were noted in aminotransferase activities, creatine phosphokinase activity, or 
C-reactive protein level. 
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Table II. Effect of 8-week treatment with simvastatin 20 mg/d, simvastatin 20 mg/d + 
fenofibrate 160 mg/d, and simvastatin 20 mg/d + fenofibrate 160 mg/d + 
nicotinic acid 1 g/d on metabolic parameters in patients with type 2 diabetes 
(N = 20). Values are shown as mean (SD) unless otherwise indicated. 
Simvastatin + 
Simvastatin + Fenofibrate + 
Parameter Simvastatin Fenofibrate Nicotinic Acid 
Lipoprotein level, mg/dL 
Total cholesterol 169 (30) 159 (25) 157 (25) 
Triglycericles 209 (135) 157 (84) 148 (85) 
HDL-C 37 (5) 39 (5) 42 (5) 
VLDL+IDL-C 42 (24) 30 (15) 27 (12) 
VLDL+lDL-apolipoprotein B 30 (13) 22 (10) 21 (10) 
Total-apolipoprotein B 106 (25) 93 (23) 87 (21) 
Non-HDL-C 132 (31) 120 (28) 115 (28) 
LDL-C 91 (23) 90 (20) 88 (22) 
LDL-apolipoprotein B 76 (18) 71 (17) 67 (15) 
LDL particles 
LDL size, A 259 (7) 263 (6) 265 (7) 
Large LDL, %* 33.2 (12.4) 41.8 (12.9) 48.7 (15.9) 
Intermediate LDL, %* 33.5 (7.7) 35.8 (6.4) 33.4 (7.5) 
Small LDL, %* 33.4 (16) 22.4 (14.7) 17.4 (16.3) 
Large LDL/intermediate + 
small LDL ratio 0.6 (0.6) 0.8 (0.5) 1.2 (0.8) 
Other measures 
hs-CRP, mg/L 4.3 (3.2) 3.3 (2.8) 3.9 (2.6) 
Median 3.6 2.9 3.4 
Glucose, mg/clL 134.3 (36.2) 127.0 (32.0) 148.2 (43.3) 
Glycosylatecl hemoglobin, % 6.5 (0.8) 6.9 (0.9) 6.9 (0.9) 
AST, IU/L 19.4 (6.3) 19.6 (2.8) 20.7 (4.5) 
ALT, IU/L 27.3 (9.2) 27.2 (9.2) 25.3 (7.6) 
CPK, IU/L 186.9 (215.0) 162.0 (141.1) 186.4 (161.1) 
HDL-C = high-density lipoprotein cholesterol; VLDL = very-low-density lipoprotein; IDL-C = intermediate- 
density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; hs-CRP = high-sensitivity 
C-reactive protein; AST = aspartate aminotransferase; ALT = alanine aminotransferase; CPK = creatine 
phosphokinase. 
*Percentage of total LDL measured by the Lipoprint System (Quantimetrix Inc., Redondo Beach, 
California). 
DISCUSSION 
This study was carried out to determine the effectiveness of the combination of 
2 triglyceride-lowering drugs (fenofibrate + low-dose nicotinic acid) for the 
treatment of diabetic dyslipidemia when added to statin treatment. It was 
prompted by the fact that both fenofibrate and low-dose nicotinic acid are well 
tolerated in patients with diabetes, whereas higher doses of nicotinic acid, 
although perhaps more effective, are accompanied by more adverse effects 
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Table III. P values obtained by analysis of variance and percentage changes in meta- 
bolic parameters after 8 weeks of t reatment wi th  simvastatin 20 mg/d 
monotherapy, simvastatin 20 mg/d + fenofibrate 160 mg/d, and simvastatin 
20 mg/d + fenofibrate 160 mg/d + nicotinic acid 1 g/d treatment in patients 
with type 2 diabetes (N = 20). 
Simvastatin + 
Simvastatin vs Fenofibrate vs 
Simvastatin vs Simvastatin + Simvastatin + 
Simvastatin + Fenofibrate + Fenofibrate + 
Fenofibrate Nicotinic Acid Nicotinic Acid 
Parameter P % A P % A P % A 
Lipoprotein level, mg/dL 
Total cholesterol 0.018 -5.9 0.015 -7.1 0.488 -1.3 
Triglycerides 0.014 -24.9 0.004 -29.2 0.538 -5.7 
HDL-C 0.008 +5.4 <0.001 +13.5 0.008 +7.7 
VLDL+IDL-C 0.004 -28.6 0.001 -35.7 0.24 -10.0 
VLDL+lDL-apolipoprotein B <0.001 -26.7 0.005 -30.0 0.49 4 .5  
Total-apolipoprotein B <0.001 -12.3 <0.001 -17.9 0.091 -6.5 
N on-H D L-C 0.004 -9.1 0.001 -12.9 0.214 4 .2  
LDL-C 0.87 -1.1 0.578 -3.3 0.51 6 -2.2 
LDL-apolipoprotein B 0.047 -6.6 0.014 -11.8 0.173 -5.6 
LDL particle 
LDL size, A, <0.001 +1.5 <0.001 +2.3 0.022 +0.8 
Large LDL, % <0.001 +25.9 <0.001 +46.7 0.027 +16.5 
Intermediate LDL, % 0.151 +6.9 0.974 -0.3 0.07 -6.7 
Small LDL, % <0.001 -32.0 <0.001 -47.9 0.05 -22.3 
Large LDL/intermediate + 
small LDL ratio 0.024 +33.3 0.008 +100 0.045 +50.0 
Other measures 
hs-CRP, mg/L 0.049* -23.3 0.73* -9.3 0.28* -18.0 
Glucose, mg/dL 0.32 -5.4 0.218 +10.3 0.035 +16.7 
Glycosylated hemoglobin, % <0.001 +6.2 0.009 +6.2 0.847 0 
AST, IU/L 0.914 +1.0 0.267 +6.7 0.307 +5.6 
ALT, IU/L 0.936 -0.4 0.058 -7.3 0.075 -7.0 
CPK, IU/L 0.479 -13.4 0.985 -0.3 0.415 +15.2 
HDL-C = high-density lipoprotein cholesterol; VLDL = very-low-density lipoprotein; IDL-C = intermediate- 
density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; hs-CRP = high-sensitivity 
C-reactive protein; AST = aspartate aminotransferase; ALT = alanine aminotransferase; CPK = creatine 
phosphokinase. 
*Data were log transformed. 
(notably, a worsening of glucose tolerance). 1° If the combinat ion of fenofibrate + 
low-dose nicotinic acid were to produce a 30% reduction in triglyceride level 
and a 30% increase in HDL-C level and still be well tolerated, it might be used in 
place of higher doses of nicotinic acid. 
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Treatment with 3 drugs was associated with a significant reduction in triglyc- 
eride levels (-29.2%) compared with simvastatin monotherapy. This would be 
considered clinically acceptable; however, there was not a significant incremen- 
tal reduction in triglyceride level when nicotinic acid 1 g was added to the 
2-drug treatment. This suggests that the triglyceride-lowering effect of fenofibrate 
and nicotinic acid is not cumulative. The drugs might have overlapping mecha- 
nisms of effect that prevent hem from having a cumulative ffect in reducing 
levels of plasma triglycerides. 
Addition of the combinat ion to s imvastat in t reatment  only raised HDL-C 
by 13.5%, well below the anticipated 30.0% increase. In patients without dia- 
betes, f ibrates will raise HDL-C levels by -10%. 29 In a 2002 study in 148 patients 
with type 2 diabetes, 12 nicotinic acid 1 g/d was associated with a significant 
increase of -20% (P< 0.05) in HDL-C. If the 2 drugs had a cumulat ive ffect on 
HDL-C, it would be expected that the levels would increase by -30%. Clearly 
this did not occur  in our study, which leads us to believe that the combina- 
tion of fenofibrate ÷ low-dose nicotinic acid does not appear  to be particu- 
larly promising for the purposes  of achieving significant increases in HDL-C 
levels. 
Adding fenofibrate ÷nicotinic acid to simvastatin monotherapy, nonetheless, 
was associated with other positive changes in the l ipoprotein profile. For exam- 
ple, total-apol ipoprotein B levels were reduced by 17.9%, which should sub- 
stantially reduce the risk for ASCVD. Much of this reduction occurred in the 
VLDL÷IDL-apolipoprotein B portion, which is rich in atherogenic remnant 
l ipoproteins. 26 Furthermore,  the 3-drug treatment was associated with a more 
favorable pattern of LDL particles (ie, a shift from small to larger particles). 3° 
In this s tudy it was difficult to be certain that adding nicotinic acid 1 g/d was 
better  than fenofibrate alone for these additional ipoprotein end points. A 
larger trial would be required to answer this question, although there was a 
nonsignif icant improvement in the l ipoprotein profile with the addition of low- 
dose nicotinic acid. 
One important question is whether adding fenofibrate is sufficient o reduce 
the residual risk for ASCVD in patients with diabetic dyslipidemia who are treated 
with statins. Several previous tudies have suggested that fibrate treatment alone 
significantly reduces the risk in patients with hypertriglyceridemia, whether with 
or without diabetes. 13-17 In a recent clinical trial, the use of fenofibrate in patients 
with type 2 diabetes, regardless of lipoprotein profile and coexisting statin treat- 
ment, reduced the risk for total ASCVD by 11%. 17 The Action to Control Cardio- 
vascular Risk in Diabetes trial 31 is being sponsored by the National Institutes 
of Health to test the efficacy of simvastatin ÷fenofibrate for reducing major coro- 
nary events in patients with type 2 diabetes. Again, inclusion in the study was not 
based on baseline lipid levels. In our opinion, it is unfortunate that in these recent 
trials, 17,31 participants were not selected on the basis of diabetic dyslipidemia, 
because prior evidence 32 has suggested that the benefits of fibrate treatment 
appear to be limited largely to patients with dyslipidemia. 
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Another important question is whether nicotinic acid would be preferable to a 
fibrate as adjunctive treatment for diabetic dyslipidemia. In a secondary preven- 
tion trial, nicotinic acid was associated with a reduced risk for recurrent major 
coronary events. 22,23 This benefit also appears to extend to patients with diabetes. 32 
In addition, the combination of a statin and nicotinic acid appears to have a favor- 
able effect on progression of atherosclerotic plaques, as suggested on coronary 
angiography 33and by carotid sonography. 34One large (N = -3300) clinical trial, the 
AIM HIGH: Niacin Plus Statin to Prevent Vascular Events study 35 sponsored by the 
National Institutes of Health, intends to determine whether the combination of a 
statin and nicotinic acid would reduce the risk for major coronary events. 
However, despite the good track record of nicotinic acid in risk reduction, the 
problem of adverse ffects at higher doses for patients with diabetes remains. 
The adverse effects of both fenofibrate and nicotinic acid are well known. 36 
Our small s tudy adds little new information about  potential ly adverse inter- 
actions. However, if a larger trial is undertaken, attention must  be given to such 
possible interactions. 
The study was part ly limited by its design. It was designed as a sequential 
drug study to facilitate complet ion with the fewest number  of patients. The 
results would have been attenuated had an intent-to-treat nalysis been done. 
The latter type of analysis is particularly appropr iate for large-scale clinical tri- 
als in which clinical recommendat ions  are to be made based on the findings. The 
present study was carried out to determine the potential utility of such a large 
study. There was no expectation that the current s tudy would serve as a basis 
for general clinical recommendat ions  about use of 3-drug treatment.  
This s tudy was a prel iminary exploration of the combinat ion of fenofibrate + 
low-dose nicotinic acid in the t reatment  of patients with diabetic dyslipidemia. 
It was an effort to assess the potential  effectiveness of adjunctive drugs with 
statin treatment.  The addition of fenofibrate was associated with the expected 
responses.  Unfortunately, the projected increases in HDL-C were not found with 
the addition of low-dose nicotinic acid. This suggests that a higher dose of nico- 
tinic acid will be required to obtain the full benefit of the combinat ion of feno- 
fibrate + nicotinic acid. A larger study or one using a higher dose of nicotinic acid 
(eg, 1.5 or 2 g/d) might reveal a benefit not evident in the current small s tudy 
using a low dose of nicotinic acid. Considering the high residual risk in patients 
with diabetes, even after t reatment  with statins, and the potential for risk reduc- 
tion associated with both fenofibrate and nicotinic acid, it might be worthwhi le 
to pursue more detailed studies of the benefits of 3-drug t reatment  for diabetic 
dyslipidemia. 
CONCLUSIONS 
Treatment with the 3-drug combinat ion was associated with a significant reduc- 
tion in triglyceride levels compared with simvastatin monotherapy. However, 
there was not a significant incremental reduction in triglyceride levels when nico- 
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tinic acid was added to the 2-drug treatment,  suggesting that the triglyceride- 
lowering effect of fenofibrate +nicotinic acid is not cumulative. To obtain clinically 
meaningful responses,  particularly for the treatment of HDL-C, higher doses of 
nicotinic acid might be required. 
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